Medovent Elixir

Ambroxol, the active ingredient in Medovent Elixir, is a mucolytic presented as an oral elixir for oral use. It reduces the viscosity of bronchial secretions and is employed in the management of respiratory conditions that produce thick, productive coughs in adults and children.

GNH USA supplies Medovent Elixir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides regulatory‑compliant documentation for cross‑border distribution.

Ambroxol is a mucolytic that acts on the respiratory tract to facilitate clearance of thick mucus. - Acute bronchitis: helps loosen mucus, improving cough effectiveness. - Chronic obstructive pulmonary disease (COPD): aids in reducing sputum viscosity for easier expectoration. - Respiratory tract infections with productive cough: supports clearance of secretions and relieves cough. - Bronchiectasis: assists in managing chronic mucus accumulation and reducing infection risk.

Ambroxol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild stomach upset occurring shortly after ingestion. - Taste disturbance: a temporary bitter or salty taste in the mouth. - Abdominal discomfort: mild cramps or discomfort in the stomach area. - Diarrhea: loose stools that usually resolve without treatment. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or anaphylaxis in susceptible individuals. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Eosinophilic pneumonia: rare inflammatory lung condition. - Blood dyscrasias: neutropenia or agranulocytosis.

When prescribing Ambroxol, clinicians should consider several precautionary measures to ensure safe use. - Hypersensitivity: avoid use in patients with known allergy to ambroxol or related compounds. - Hepatic impairment: use with caution; monitor liver function tests. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Pediatric use: not recommended for children under 2 years of age unless specifically advised. - Gastrointestinal bleeding: monitor patients with a history of ulcers or on anticoagulants. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Ambroxol can interact with other medicines, altering their effectiveness or safety profile.

Major Interactions (Avoid): - Warfarin: ambroxol may potentiate anticoagulant effect, increasing bleeding risk. - Anticholinergic cough suppressants: may reduce mucociliary clearance, counteracting ambroxol’s benefit.

Moderate Interactions (Monitor Closely): - Bronchodilators (e.g., salbutamol): additive bronchodilatory effect may cause excessive airway relaxation. - Other mucolytics (e.g., N‑acetylcysteine): combined use may increase gastrointestinal irritation. - CYP2D6 substrates (e.g., metoprolol): ambroxol may inhibit metabolism, requiring dose review. - Antihistamines: potential for enhanced sedation or anticholinergic burden.